Telomir Pharmaceuticals, Inc. Common Stock

NASDAQ:TELO

Biotechnology

Healthcare
$0.69 -3.42%

-$0.04 today

Market cap
$50.84M
Beta
-0.24
P/E (TTM)
-3.8
EPS (TTM)
-$0.27
52W Low $0.89High $2.09

Volume 0.17M

Average 0.13M

Big Five Numbers

Telomir Pharmaceuticals, Inc. Common Stock growth analysis

Start with the long-run numbers that show whether TELO compounds: return on capital and growth in sales, earnings, equity, and free cash flow.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
Not availableNot availableNot availableNot available
Revenue
Not availableNot availableNot availableNot available
Equity
Not availableNot availableNot available+758.2%
Cash
Not availableNot available+1,625.2%+475.5%
ROIC
Not available-306.4%-646.2%-165.0%

Analysis

In the latest year, Equity was strongest at +758.2%, while ROIC was weakest at -165.0%. The three-year average ROIC was -646.2%, a measure of how efficiently the company earned that growth.

Growth analysis

Is growth accelerating or fading?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A —
RevenueN/AN/AN/A
N/A —
Net IncomeN/AN/AN/A
N/A —
EBITN/AN/AN/A
N/A —

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Revenue segments

Where does the growth come from?

Break revenue down by product and geography to see which parts of the business drive the trend.

Revenue by segment

Where TELO earns its revenue, as reported in company filings

This company does not report revenue segments.

Free cash flow

Does growth turn into cash?

Check whether reported growth converts into free cash flow after capital spending.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

FY2025

= Net Income-$10.4M
+ D&A$0
+ Stock-Based Comp$5.3M
+ Deferred Tax$0
+ Working Capital$594.7K
+ Other Non-Cash$840.0K
= Operating Cash Flow-$3.7M
- Capex$0
= Free Cash Flow-$3.7M

Analysis

FY2025 free cash flow is -$3.7M. FCF conversion is 35.4% of net income. Operating cash flow was -$3.7M, with capex of $0. The largest bridge item is Stock-Based Comp at $5.3M.

Price targets

What do analysts expect from the price?

Compare the current price with the low, average, and high analyst targets.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for TELO.

Sign in free

Analyst ratings

How do analysts rate the stock?

Review the buy, hold, and sell split and recent upgrades and downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

No analyst ratings available.

Competitor growth

How does Telomir Pharmaceuticals, Inc. Common Stock grow against peers?

Compare historical and forecast growth with similar companies.

Competitor Growth

Peer CAGR comparison & forward estimates

CompanyMarket Cap10yr5yr3yrFwd

Century Therapeutics, Inc.

IPSC

$266.18M——+175.9%
-17.0% (5yr)2 analysts

Equillium, Inc.

EQ

$86.87M———
—0 analysts

INmune Bio, Inc.

INMB

$40.24M—+35.4%-48.9%
+407.7% (5yr)1 analysts

Coeptis Therapeutics Holdings, Inc.

COEP

$38.62M—+113.5%—
-25.0% (2yr)1 analysts

Karyopharm Therapeutics Inc.

KPTI

$15.02M+89.1%+6.2%-2.4%
+33.2% (5yr)3 analysts

Questions

Growth questions

Common questions about TELO's growth, answered from reported and forecast figures.